Open an account

Sanara Medtech

SMTI · NASDAQ

$33.14+$0.00 (+0.00%)TodayMarket closed ·
Prev close $33.14

About SMTI

Sanara MedTech, Inc. engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 108 full-time employees. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. The company markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.

Employees
108
Headquarters
Fort Worth, Texas
Listed
Apr 7, 1994
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
sanaramedtech.com

SMTI key statistics

Market cap
304.49M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
201.85K
Volume
86.31K
Open price
$33.16
High today
$33.64
Low today
$32.71
52 Week high
$35.52
52 Week low
$16.05

Sanara Medtech (SMTI) at a glance

Sanara Medtech (SMTI) last traded at $33.14, with a market cap of 304.49M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $32.71 and $33.64. The current price is 1.3% above the day's low and 1.5% below its high.

Volume so far is 86.31K shares, below the average of 201.85K shares a day.

Over the past year Sanara Medtech has ranged from $16.05 to $35.52, and now sits 88% of the way up that range.

Sanara Medtech met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.05 per share against an estimate of -$0.0255.

The average analyst price target is $35.70, 7.7% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 3 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 5 analystsAvg $35.70
Low
$35.35
Now
$33.14
High
$36.75

SMTI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 78.8% on average.

  1. Q3 FY24: reported -$0.34 per share against an estimate of -$0.6324
  2. Q4 FY24: reported -$0.18 per share against an estimate of -$0.1173
  3. Q1 FY25: reported -$0.412 per share against an estimate of -$0.5151
  4. Q2 FY25: reported -$0.23 per share against an estimate of -$0.4488
  5. Q3 FY25: reported $0.09 per share against an estimate of -$0.2193
  6. Q4 FY25: reported $0.09 per share against an estimate of $0.1122
  7. Q1 FY26: reported $0.05 per share against an estimate of -$0.1326
  8. Q2 FY26: reported -$0.05 per share against an estimate of -$0.0255

SMTI news

  • Press releasePRNewswire

    Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?

  • Press releaseBusiness Wire

    Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

  • Press releaseBusiness Wire

    SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders

  • Press releasePRNewswire

    Are MKTX, SMTI, FBRX, LXFR Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger--FBRX, LXFR, SMTI, and MKTX

  • Press releasePRNewswire

    Are MKTX, SMTI, LPSN Obtaining Fair Deals for their Shareholders?

  • Press releaseBusiness Wire

    Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sanara MedTech Inc. (NASDAQ: SMTI)

Similar companies

Companies in the same industry as Sanara Medtech

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.